Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by cacfacmaon May 03, 2023 12:34pm
191 Views
Post# 35427805

SQI Diagnostic Prospects

SQI Diagnostic ProspectsI have been a silent observer on the sidelines for the past few years but need to take the opportunity to say something now. 

The reason I invested in the company originally was because of its great technology, such as Rali-fast, Rali-dx POC, and Tordx Lung, which are all potential game changers to health care.  As those familiar with the story already know, the path to commercialization is much clearer now than it was even a year ago. $10 million would be enough to see the company through at least another year of operations and to let one or more of these opportunites come to commercialization.  

I understand and appreciate that the three majority shareholders have supported the company to the tune of tens of millions of dollars over the years and that the company would not be where it is today without them.  I also appreciate the fact that everybody has a tolerance for how much they want to invest in a single company.

However, what I cannot understand is how the company is having difficult raising capital from outside investors.  Given the addressable market, in the US alone, of more than $1.4 billion dollars per year for their suite of products, this should be an easy task.  

Hopefully another poster here can outline what I am missing.




<< Previous
Bullboard Posts
Next >>